Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

NCT03521245 · clinicaltrials.gov ↗

UNKNOWN

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

OTHER: RNA sequencing
OTHER: Transcriptome analysis
DRUG: Trastuzumab
DRUG: Chemotherapy

Sponsor

OmicsWay Corp.

Collaborators

[object Object]
[object Object]
[object Object]